NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/24/2025
Back to search
Official data from USPTO
DILUOSIKANG
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
17
Latest update
06/24/2025
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
08/30/2024
Registration date
06/24/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/24/2025
Last transaction
06/24/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
08/21/2024
First use in commerce
08/21/2024
Drawing code
3
Owner type
99
Owner location
Guangdong Province, CN
Examiner
LINDEMANN, ROBIN
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of black stylized Chinese characters and stylized wording "Diluosikang".
Holders and representatives
Holders
Zhaoqing Tianying Biotechnology Co., Ltd.
Representatives
Edward Darius Robinson
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Biological preparations for the treatment of cancer; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Gummy vitamins; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Mixed biological preparations for the prevention and treatment of infectious diseases; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Pharmaceutical preparationsa drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Sugar replacement for medicinal or therapeutic purposes; Tumor suppressing agents
Publications
History of USPTO decisions and trademark events.
17 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/24/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/06/2025
PUBO
PUBLISHED FOR OPPOSITION
05/06/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/30/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/02/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/28/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/28/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/28/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/17/2025
GNRT
NON-FINAL ACTION E-MAILED
03/17/2025
CNRT
NON-FINAL ACTION WRITTEN
03/17/2025
RFTP
REMOVED FROM TEAS PLUS
03/17/2025
DOCK
ASSIGNED TO EXAMINER
03/13/2025
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
03/12/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/12/2025
NWAP
NEW APPLICATION ENTERED
08/30/2024
Continuous trademark protection
Get notified about every new filing that threatens DILUOSIKANG or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.